Search

Your search keyword '"Teo C"' showing total 31 results
Start Over Author "Teo C" Publisher wiley
31 results on '"Teo C"'

8. Autochthonous hepatitis E in southwest England

Author

Dalton, H. R., primary, Thurairajah, P. H., additional, Fellows, H. J., additional, Hussaini, H. S., additional, Mitchell, J., additional, Bendall, R., additional, Banks, M., additional, Ijaz, S., additional, Teo, C.‐G., additional, and Levine, D. F., additional

Published
2006
Full Text
View/download PDF

29. Drug resistance of a viral population and its individual intrahost variants during the first 48 hours of therapy.

Author

Campo DS, Skums P, Dimitrova Z, Vaughan G, Forbi JC, Teo CG, Khudyakov Y, and Lau DT

Subjects
Algorithms, Drug Therapy, Combination, Genetic Variation, Humans, Molecular Sequence Data, Phylogeny, Population, Predictive Value of Tests, RNA, Viral genetics, RNA, Viral isolation & purification, Real-Time Polymerase Chain Reaction, Recombinant Proteins therapeutic use, Treatment Outcome, Viral Load, Antiviral Agents therapeutic use, Drug Resistance, Viral physiology, Hepacivirus drug effects, Hepatitis C drug therapy, Hepatitis C virology, Interferon-alpha therapeutic use, Polyethylene Glycols therapeutic use, Ribavirin therapeutic use
Abstract

Using hepatitis C virus (HCV) and interferon (IFN) resistance as a proof of concept, we have devised a new method for calculating the effect of a drug on a viral population, as well as the resistance of the population's individual intrahost variants. By means of next-generation sequencing, HCV variants were obtained from sera collected at nine time points from 16 patients during the first 48 h after injection of IFN-α. IFN-resistance coefficients were calculated for individual variants using changes in their relative frequencies, and for the entire intrahost viral population using changes in viral titer. Population-wide resistance and presence of IFN-resistant variants were highly associated with pegylated IFN-α2a/ribavirin treatment outcome at week 12 (P = 3.78 × 10(-5) and 0.0114, respectively). This new method allows an accurate measurement of resistance based solely on changes in viral titer or the relative frequency of intrahost viral variants during a short observation time.

Published
2014
Full Text
View/download PDF

30. Advanced breast cancer-are we doing enough?

Author

Pek CH, Tan EY, Chen JJ, Ho PW, Teo C, Earnest A, and Chan PM

Subjects
Breast Neoplasms epidemiology, Breast Neoplasms ethnology, Carcinoma, Intraductal, Noninfiltrating diagnosis, Early Detection of Cancer, Female, Humans, Mass Screening, Retrospective Studies, Singapore epidemiology, Singapore ethnology, Breast Neoplasms diagnosis, Breast Neoplasms pathology, Carcinoma, Intraductal, Noninfiltrating pathology
Published
2012
Full Text
View/download PDF

31. Cerebrospinal fluid pharmacokinetics of cefpodoxime proxetil in piglets.

Author

Abdel-Rahman SM, Maxson S, Teo C, Hubbard AE, and Kearns GL

Subjects
Animals, Ceftizoxime blood, Ceftizoxime cerebrospinal fluid, Ceftizoxime pharmacokinetics, Cephalosporins blood, Cephalosporins pharmacokinetics, Swine, Cefpodoxime Proxetil, Ceftizoxime analogs & derivatives, Cephalosporins cerebrospinal fluid
Abstract

Cefpodoxime is an oral third-generation cephalosporin used for the treatment of acute upper-respiratory tract infections caused by susceptible bacteria in children. Although not indicated for the treatment of bacterial meningitis, it is used to treat other infections produced by organisms associated with meningitis and may obscure the result of cerebrospinal fluid (CSF) cultures in children who develop meningitis while receiving oral antibiotics if sufficient concentrations are achieved in the CSF. This study evaluated the disposition of cefpodoxime and penetration into CSF in piglets. Fifteen Landacre-Camborough cross piglets (10-20 days old) received cefpodoxime proxetil oral suspension (10 mg/kg). Repeated plasma and CSF samples were collected over 24 hours for quantitation of cefpodoxime by HPLC. Pharmacokinetic analysis was performed on both plasma and CSF data. The plasma concentration versus time data for cefpodoxime were best characterized using a one-compartment model with first-order absorption. The mean (+/- SD) pharmacokinetic parameters for Cmax, tmax, and AUC0-infinity were 23.3 +/- 12.9 mg/L, 3.9 +/- 1.4 h, and 237 +/- 129 mg/L.h, respectively. CSF/plasma ratios for AUC0-infinity demonstrated a mean cefpodoxime penetration of approximately 5%. CSF penetration of cefpodoxime was evident following a single oral dose of cefpodoxime proxetil suspension. Despite the small percentage of total cefpodoxime dose distributing into the CSF, the resultant concentrations approached or exceeded the MIC90 for many bacterial pathogens considered susceptible to cefpodoxime. Accordingly, clinicians should use caution in the interpretation of CSF cultures in patients who develop clinical signs and symptoms consistent with meningitis and who have been previously treated with cefpodoxime.

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results